Dr Lal PathLabs Q4 net up 27% at Rs 40 cr

We are in the last phase of the September quarter earnings season, and the results announced by the BSE 500 companies so far have shown signs of a sharp recovery, as compared to the June quarter, when the economic activity in the country was compromised due to lockdown in various regions. From the BSE 500 list, 216 companies have announced their September quarter results so far. We excluded banking and financial companies.  Along with the index stocks we also analyse each sector quarterly earnings. (Data Source: ACE Equity)

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Diagnostic chain Dr Lal PathLabs today reported 27.21 percent rise in consolidated net profit to Rs 40.2 crore for the quarter ended March 31, 2018. The company had posted a net profit of Rs 31.6 crore during January-March, 2016-17, Dr Lal PathLabs said in a filing to BSE.

Consolidated operating revenue rose to Rs 266.8 crore for the quarter under review. It was Rs 219.9 crore for the same period a year ago.

For entire 2017-18, the company's net profit rose to Rs 171.8 crore as against Rs 155.6 crore in 2016-17. Consolidated operating revenue for the year stood at Rs 1,056.9 crore. It was Rs 912.4 crore in the previous financial year.

The company's board has recommended a final dividend of Rs 3 per equity share of Rs 10 each for 2017-18. This is in addition to the interim dividend of Rs 1.50 already paid out, Dr Lal PathLabs said. Its shares today closed at Rs 806.10 per scrip on BSE, down 1.26 percent from previous close.